Distinct Myogenic Stages Recapitulate Transcriptomic Networks in COPD Cachexia

BackgroundCachexia is an extrapulmonary manifestation of Chronic Obstructive Pulmonary Disease (COPD) characterized by weight loss and muscle wasting. Transcriptomic profiling of vastus lateralis biopsies enables profiling of COPD-cachexia relevant dysregulation. As obtaining muscle biopsies is invasive and yields limited tissue, human muscle derived cultures (HMDC) may enable mechanistic research into cachexia. However, questions remain regarding the extent to which HMDC recapitulate transcriptomic signatures of bulk skeletal muscle in COPD-cachexia. To address this gap, we tested whether COPD and COPD-cachexia associated transcriptional dysregulation signatures in bulk skeletal muscle are preserved in derived myoblasts, myocytes, and myotubes. MethodsVastus lateralis biopsies were collected from 13 (6M/7F, 64{+/-}9 years) participants; COPD n=5, COPD-cachexia n=4, and 4 age-matched controls. Cachexia was defined using a composite measure of weight loss coupled with reduced muscle strength, fatigue, anorexia, low muscle mass and/or systemic inflammation. Satellite cells were isolated and differentiated into myoblasts, myocytes, and myotubes. Differential gene expression testing, generated from RNA-sequencing, identified transcripts significantly dysregulated (p>0.05) in bulk tissue. Weighted gene co-expression network analysis (WGCNA) was performed to identify modules of co-expressed genes at the whole-transcriptome and mitochondrial transcriptome levels. Bulk tissue modules were tested for preservation in HMDC (Z-summary >2) and correlated with clinical traits. Gene set enrichment analysis was performed for all modules. Results1,379 genes were significantly differentially expressed in bulk samples from all COPD participants compared to controls. The top upregulated gene was IL32 (L2FC=4.5, p=1.3x10-3) and top downregulated CGN (L2FC=-5.8, p=8.8x10-3). A total of 632 genes were significantly differentially expressed in bulk samples from COPD participants with and without cachexia. The top upregulated gene was SEMA4F (L2FC=5.0, p=6.9x10-4) and top downregulated ARC (L2FC=-4.9, p=3.1x10-2). WGCNA generated 9 modules (Modules 1 - 9) at the whole-transcriptome level and 2 modules (Modules A and B) at the mitochondrial transcriptome level. Modules 1, 4, 5, and 9 were significantly correlated with COPD-cachexia. Of these, module 1 was preserved in myoblasts and modules 4, 5 and 9 in myocytes. These modules are enriched with genes involved in metabolic and inflammatory remodeling, catabolic stress and atrophy, and chromatin-driven regeneration. ConclusionsThese results provide a foundation for using myocytes and myoblasts as in vitro models of degeneration and repair pathway dysregulation in COPD-cachexia. Several modules were preserved between bulk skeletal muscle and HMDC, suggesting HMDC have utility for studying COPD-cachexia.